-
1.发明申请公开(公告)号：US20190248906A1
公开(公告)日：2019-08-15
申请号：US16282834
申请日：2019-02-22
Applicant: Amgen, Inc.
Inventor： Yang LI , Jennitte LeAnn STEVENS , Chadwick Terence KING , Ian Nevin FOLTZ , Gunasekaran KANNAN , Junming YIE , Shaw-Fen Sylvia HU
CPC classification number: C07K16/2863 , A61K2039/505 , C07K14/71 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2319/00 , C07K2319/30 , C12Y302/01031
Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
-
公开(公告)号：US20220144920A1
公开(公告)日：2022-05-12
申请号：US17420231
申请日：2020-01-02
Applicant: AMGEN INC.
Inventor： Jennitte LeAnn STEVENS , Deniz TEMEL , Bram ESTES , Neeraj Jagdish AGRAWAL
IPC: C07K16/00
Abstract: Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.
-
Patent Agency Ranking
3.发明申请公开(公告)号：US20170183412A1
公开(公告)日：2017-06-29
申请号：US15400800
申请日：2017-01-06
Applicant: Amgen Inc.
Inventor： Yang LI , Jennitte LeAnn STEVENS , Chadwick Terence KING , Ian Nevin FOLTZ , Gunasekaran KANNAN , Junming YIE , Shaw-Fen Sylvia HU
CPC classification number: C07K16/2863 , A61K2039/505 , C07K14/71 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2319/00 , C07K2319/30 , C12Y302/01031
Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
-
公开(公告)号：US20230183382A1
公开(公告)日：2023-06-15
申请号：US18046855
申请日：2022-10-14
Applicant: CytomX Therapeutics, Inc. , Amgen, Inc.
Inventor： Leila M. BOUSTANY , Madan M. PAIDHUNGAT , Ellaine Anne Mariano FOX , Sayantan MITRA , W. Michael KAVANAUGH , Raffaella BRIANTE , Jennitte LeAnn STEVENS
CPC classification number: C07K16/468 , C07K16/2863 , C07K16/2809 , C07K2317/31 , C07K2317/52 , C07K2317/565 , A61K2039/505
Abstract: The present disclosure relates to activatable anti-EGFR, anti-CD3, heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
-
公开(公告)号：US20230174995A1
公开(公告)日：2023-06-08
申请号：US18046860
申请日：2022-10-14
Applicant: CytomX Therapeutics, Inc. , Amgen, Inc.
Inventor： Leila M. BOUSTANY , Madan M. PAIDHUNGAT , Ellaine Anne Mariano FOX , Sayantan MITRA , W. Michael KAVANAUGH , Raffaella BRIANTE , Jennitte LeAnn STEVENS
CPC classification number: C12N15/62 , C12N15/63 , C07K16/2809 , C07K16/2863 , C07K2319/30 , C07K2319/50 , A61K2039/505
Abstract: The present disclosure relates to activatable heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
-
6.发明申请公开(公告)号：US20220089689A1
公开(公告)日：2022-03-24
申请号：US17491715
申请日：2021-10-01
Applicant: AMGEN INC.
Inventor： Jason C. O'NEILL , Randal R. KETCHEM , TaeWeon LEE , Vishnu CHINTALGATTU , Jennitte LeAnn STEVENS
IPC: C07K14/81
Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
-
7.发明申请公开(公告)号：US20170253889A1
公开(公告)日：2017-09-07
申请号：US15519820
申请日：2015-10-14
Applicant: AMGEN INC.
Inventor： Mark DARIS , Jennitte LeAnn STEVENS , Chi-Ming Kevin LI , Huanying GE
CPC classification number: C12N15/85 , C07K14/47 , C12N9/0008 , C12N9/88 , C12N2830/00 , C12N2830/15 , C12N2830/34 , C12N2830/42 , C12N2830/85 , C12Y102/01012
Abstract: Disclosed are a recombinant expression vector and a host cell that contains the vector.
-
-
-
-
-
-
Search Results
7
records
(took 0.02 seconds)
